A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis

Dermatitis

Volumn 18, Issue 1, 2007, Pages 26-31

  Bhardwaj, Sachin S ^a   Jaimes, Juan P ^a   Liu, An ^a   Warshaw, Erin M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID DERIVATIVE; IMMUNOMODULATING AGENT; NICKEL SULFATE; PETROLATUM; PIMECROLIMUS; PLACEBO; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MEDICAL ASSESSMENT; OINTMENT; PATCH TEST; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; SYRINGE;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ADULT; ALLERGENS; CLOBETASOL; DERMATITIS, ALLERGIC CONTACT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; NICKEL; PETROLATUM; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; TRIAMCINOLONE;

EID: 34047217678     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2007.06031     Document Type: Article

References (21)

1. Lauerma AI, Stein BD, Homey B, et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 1994;286:337-40.
2. Funk JO, Maibach HI. Horizons in pharmacologic intervention in allergic contact dermatitis. J Am Acad Dermatol 1994;31:999-1014.
3. Bornhovd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001;45:736-43.
4. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-41.
5. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
6. Nasr IS. Topical tacrolimus in dermatology. Clin Exp Dermatol 200; 25:250-4.
7. Panhans-Gros A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107:345-52.
8. Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003;121:77-80.
9. Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506. Lancet 1992;340:556.
10. Robinson N, Singri P, Gordon K. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001;20:242-9.
11. Jaimes JP, Liu A, Bhardwaj SS, Warshaw EM. Optimizing reproducibility for clinical studies involving patch testing and application of topical preparations. Dermatitis 2006;17:133-6.
12. Weissenbacher S, Traidl-Hoffman C, Eyerich K, et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006;140:239-44.
13. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992;98:851-5.
14. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
15. Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003;49:477-82.
16. Alomar A, Puig L, Gallardo CM, Valenzuela N. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis 2003;49:185-8.
17. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
18. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42:349-70.
19. Amrol D, Duane K, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91:563-6.
20. Parneix-Spake A, Goustas P, Green R. Eumovate (clobetasone butyrate) 0.05% cream with its moisturizing emollient base has better healing properties than hydrocortisone 1% cream: a study in nickel-induced contact dermatitis. J Dermatol Treat 2001;12:191-7.
21. Marks JG, Fowler JF Jr, Sheretz EF, Rietschel RL. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite. J Am Acad Dermatol 1995;33:212-6.